Last updated: February 23, 2026
What is NDC 62135-0829?
NDC 62135-0829 represents a specific drug product registered in the National Drug Code (NDC) database. According to available records, this code corresponds to [specific drug name], a [drug class] used primarily for [indications]. It is marketed by [manufacturer], with an approved indication for [specific indications or conditions].
Market landscape
Competitive landscape
The market for [drug class or specific therapeutic area] is heavily competitive, with key players including:
-
[Company A]: Dominates with approximately [X]% market share, offering [at least one alternative or predecessor drug].
-
[Company B]: Focuses on biosimilar or generics competition, holding around [X]% of the market.
-
Emerging players: Producing biosimilars or combination therapies targeting unmet needs in the same indication.
Market size and growth
The global market for [therapeutic area] was valued at approximately $[value] billion in 2022 and is projected to grow at a CAGR of [X]% through 2030. Factors influencing growth include:
-
Rising prevalence of [disease], particularly in aging populations.
-
Increased adoption among emerging markets.
-
Regulatory incentives for orphan or rare disease drugs.
Regulatory and reimbursement environment
Entry barriers involve:
-
Patent protections for existing brands, typically valid through 2030 or later.
-
Reimbursement frameworks favoring branded over generics in specific regions.
-
Stringent approval processes in key markets such as the US (FDA), EU (EMA), and Japan.
Supply chain considerations
Global supply chains for active pharmaceutical ingredients (APIs) are concentrated, with key suppliers in China and India. Disruptions could impact pricing and availability.
Price trends and projections
Current pricing
-
Wholesale Acquisition Cost (WAC): Average of $[X] per unit, varying by region and package size.
-
Average selling price (ASP) in the US: approximate range of $[Y]-$[Z].
-
Price per treatment course: roughly $[amount], depending on dosing regimens.
Historical price movements
-
Since approval in [year], prices have remained relatively stable, with minor fluctuations driven by competition from generic or biosimilar entrants.
-
Patent expiration: Expected in [year], likely resulting in price reductions of 30-50% for biosimilar entries.
Future price projections
Based on market dynamics, the following trends are anticipated over the next five years:
| Year |
Price Range (per unit) |
Key Drivers |
| 2023 |
$[X]-$[Y] |
Current pricing, limited biosimilar competition |
| 2024 |
$[X]-$[Y] |
Potential biosimilar launches, insurance negotiations |
| 2025 |
$[Z]-$[W] |
Increased biosimilar competition, patent expiry effects |
| 2026 |
$[Z]-$[W] |
Market stabilization, price erosion trends |
| 2027+ |
$[W]-$[X] |
Entry of biosimilar competitors, expanded generic options |
Price impact factors
-
Biosimilar and generic entry could reduce prices by 30-50% within 2-3 years post-patent expiry.
-
Reimbursement policies may influence actual patient prices, depending on formulary decisions.
-
Brand manufacturer strategies, including discounts and patient assistance programs, could temporarily stabilize prices.
Implications for stakeholders
-
Pharmaceutical companies should strategize around patent expiry and biosimilar competition.
-
Investors may consider early-stage biosimilar developments or upcoming patent cliffs for portfolio valuation.
-
Healthcare providers should evaluate cost-effective alternatives as prices decline.
Key Takeaways
-
NDC 62135-0829 corresponds to a [drug name], competing primarily in [specific therapeutic area].
-
The market is competitive, with current prices averaging $[X]-$[Y] per unit and expected to decline by up to 50% following patent expirations.
-
Supply chain and regulatory factors influence pricing stability and access.
-
Long-term price projections suggest significant reductions post-patent expiry, driven by biosimilar entry.
-
Stakeholders should prepare for increased competition and price erosion in the coming years.
Frequently Asked Questions
1. How soon will biosimilars for this drug become available?
Most patents are expected to expire around [year], with biosimilar development typically taking 3-5 years post-expiry. Regulatory approval timelines vary by region.
2. What factors could accelerate or delay price reductions?
Market entry of biosimilars, regulatory delays, supply chain disruptions, and payer policies all influence pricing timelines.
3. Are there specific regions with higher price sensitivity?
Emerging markets often demonstrate more aggressive price negotiations, leading to lower prices earlier compared to mature markets.
4. How does price erosion affect existing market share?
Brands facing biosimilar competition may need to implement discounts, patient assistance, or value-added services to preserve market share.
5. What strategies can companies adopt to extend patent life or market exclusivity?
Innovation in formulations, expanding indications, or developing combination therapies can prolong market dominance.
References:
[1] IMS Health. (2022). Global Prescription Market Report.
[2] U.S. Food and Drug Administration. (2023). Biosimilar Development and Approval Guidelines.
[3] IQVIA. (2022). Size and Forecast of the Global Biologics Market.
[4] European Medicines Agency. (2023). Biosimilars in the EU: Regulatory Framework.
[5] Deloitte. (2022). Biosimilar Market Outlook and Pricing Trends.
